

Name of the issue:

Alkem Laboratories Ltd

1	Type of issue (IPO/ FPO)	IPO
2	Issue size (Rs crore) <i>* Source: Basis of Allotment - pursuant to spill over of undersubscription in Employee category to Net Offer</i>	1347.7*
3	Grade of issue alongwith name of the rating agency	Not applicable
4	Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged. <i>*Source: Basis of Allotment</i>	30.8708* <i>Figure is before technical rejections and after adjusting for cheque return cases</i>
5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)	
	(i) allotment in the issue	5.3 <i>Source: Minutes for basis of allotment dated 19 Dec 2015</i>
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2015)	6.04 <i>Source: BSE Filings</i>
	(iii) at the end of 1st FY (March 31, 2016)	6.81 <i>Source: BSE Filings</i>
	(iv) at the end of 2nd FY (March 31, 2017)	6.75 <i>Source: BSE Filings</i>
	(v) at the end of 3rd FY (March 31, 2018)	6.92 <i>Source: BSE Filings</i>

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under Clause 41 of the listing agreement)

As per the annual Consolidated financial results submitted to stock exchanges

(Rs. in crores)

Parameters	1st FY (March 31, 2016)	2nd FY (March 31, 2017)	3rd FY (March 31, 2018)
Income from operations ¹	4,992	5,853	6,431
Net Profit for the period ²	673.12	869.12	611.87
Paid-up equity share capital	23.91	23.91	23.91
Reserves excluding revaluation reserves	3,478.74	4,443.73	4,839.86

Source: Alkem BSE Filings. On consolidated basis.

1. Excludes Other Operating Income

2. Includes other comprehensive income.

7	Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)	
	(i) at the end of 1st FY (Mar 31, 2016)	Frequently Traded <i>Source: Stock Exchange data</i>
	(ii) at the end of 2nd FY (Mar 31, 2017)	Frequently Traded <i>Source: Stock Exchange data</i>
	(iii) at the end of 3rd FY (Mar 31, 2018)	Infrequently traded <i>Source: Stock Exchange data</i>
8	Change, if any, in directors of issuer from the disclosures in the offer document (See Clause 30 of the listing agreement)	
	(i) at the end of 1st FY (Mar 31, 2016)	None
	(ii) at the end of 2nd FY (Mar 31, 2017)	Mr. Mangaldas Chhaganlal Shah is not a director anymore. Dr. Dheeraj Sharma became independent director
	(iii) at the end of 3rd FY (Mar 31, 2018)	Mr. Sandeep Singh - Re-designated as the Managing Director
9	Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Clause 41 (IV) (e) of the listing agreement)	
	(i) as disclosed in the offer document	Not Applicable as 100% Offer for sale
	(ii) Actual implementation	Not Applicable
	(iii) Reasons for delay in implementation, if any	Not Applicable
10	Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 41, 43 and 43A of the listing agreement)	
	(i) as disclosed in the offer document	Not Applicable as 100% Offer for sale
	(ii) Actual utilization	Not Applicable
	(iii) Reasons for deviation, if any	Not Applicable
11	Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009 read with Clause 43A of the listing agreement)	
	(a) Comments on use of funds	Not Applicable
	(b) Comments on deviation, if any, in the use of proce	Not Applicable
	(c) Any other reservations expressed by the monitorin	Not Applicable
	(To be submitted till the time the issue proceeds have been fully utilised)	

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

12 Price- related data

Issue price (Rs):

1,050 Discount if INR100 was offered to eligible employees of the Issuer

Price parameters	At close of listing day - December 23, 2015	At close of 30th calendar day from listing day - January 21, 2016 ¹	At close of 90th calendar day from listing day-March 21, 2015 ²	As at the end of 1st FY after the listing of the issue(31 Mar 2016)			As at the end of 2nd FY after the listing of the issue (31 Mar 2017)			As at the end of 3rd FY after the listing of the issue (31 Mar 2018) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price	1,381.45	1,368.00	1,347.50	1,366.50	1,589.00	1,232.00	2,206.95	2,228.55	1,175.00	1,977.00	2,468.00	1,578.00
Index (of the Designated Stock Exchange):S&P BSE Sensex (BSE being the designated stock exchange)	25,850.30	23,962.21	25,285.37	25,341.86	26,197.27	22,494.61	29,620.50	29,824.62	24,523.20	32,968.68	36,443.98	29,241.48
Sectoral Index (mention the index that has been considered and reasons for considering the same)(S&P BSE Healthcare)	16,715.68	15,173.51	15,441.68	15,149.25	17,068.02	14,418.86	15,312.40	16,865.85	13,955.44	13,157.62	15,578.06	12,513.13

1. 30th calendar day has been taken as listing date plus 29 calendar days
2. 90th calendar day has been taken as listing date plus 89 calendar days
3. Based on prices as of 28 Mar 2018

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

13 Basis for Issue Price and Comparison with Peer Group & Industry Average (On consolidated basis)

Accounting ratio	Name of company	As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009) ¹	At the end of 1st FY (March 31, 2016) ²	At the end of 2nd FY (March 31, 2017)	At the end of 3rd FY (March 31, 2018)
EPS	Issuer: Alkem Laboratories Limited	38.7	56.3	74.6	52.8
	Peer Group: Torrent Pharmaceuticals Limited	44.4	101.78	55.2	40.07
	Peer Group: Ipca Laboratories Limited	20.2	7.39	15.4	18.97
	Peer Group: Alembic Pharmaceuticals Limited	15.0	38.16	21.4	21.9
	Industry Avg:	26.5	49.1	30.7	27.0
P/E	Issuer: Alkem Laboratories Limited	27.1	24.3	29.6	37.5
	Peer Group: Torrent Pharmaceuticals Limited	34.8	13.2	28.1	31.14
	Peer Group: Ipca Laboratories Limited	38.8	78.5	40.4	34.52
	Peer Group: Alembic Pharmaceuticals Limited	45.2	15.7	29.2	25.12
	Industry Avg:	39.6	35.8	32.6	30.3
RoNW	Issuer: Alkem Laboratories Limited	15.4%	19.2%	20.0%	13.1%
	Peer Group: Torrent Pharmaceuticals Limited	30.2%	50.8%	21.5%	14.7%
	Peer Group: Ipca Laboratories Limited	11.5%	4.1%	7.9%	8.9%
	Peer Group: Alembic Pharmaceuticals Limited	32.0%	44.9%	21.2%	20.0%
	Industry Avg:	24.6%	33.3%	16.9%	14.5%
NAV per share based on balance sheet	Issuer: Alkem Laboratories Limited	250.5	292.9	373.7	406.8
	Peer Group: Torrent Pharmaceuticals Limited	147.2	200.3	257.1	273.1
	Peer Group: Ipca Laboratories Limited	175.0	181.0	194.6	213.0
	Peer Group: Alembic Pharmaceuticals Limited	46.9	84.9	100.8	117.8
	Industry Avg:	123.0	155.4	184.2	201.3

1. Source: Prospectus dated Dec 15, 2015

2. Source: Respective BSE Result Filings. On consolidated and diluted basis

14 Any other material information

Particulars	Date
Company provided a clarification on news report captioned "Drug Regulator finds Alkem Labs drug substandard again" that the batches of Glimikem referred to by CDSCO were based on older formulation and that subsequently formulation had been improvised	9-Jun-16
With respect to the news reports in the media in connection with 'Notification to the CHMP/EMA Secretariat of a Referral under Article 31 of Directive 2001/83/EC' (the "Directive") made by The Federal Institute of Drug and Medical Devices (BfArM) Germany. Company provided clarity on the issue that after the inspection of March 2015 by German regulator, BfArM, Alkem had responded to the regulator with a robust remedial plan and has also been implementing several measures which included changes in staffing, upgrading equipment and improving quality assurance systems to ensure proper controls during bioequivalence studies and thorough review of the acquired data	16-Apr-16
Some of the promoters of Alkem Laboratories Ltd ("Company") comprising of Mr. Samprada Singh and his lineal descendants, Mr. Balmiki Prasad Singh, Mrs. Manju Singh, Mr. Sarandhar Singh, Mr. Srinivas Singh, Mr. Satish Kumar Singh, Mrs. Premlata Singh, Mr. Sarvesh Singh, Mrs. Annapurna Singh, Mr. Sandeep Singh and Mrs. Inderjit Arora; and the Samprada Singh HUF have entered into a family settlement on March 23, 2016 with a view to ensure preservation of the shareholding and control of the Company within the family. Pursuant to the family settlement, the aforementioned members of the family will transfer their shareholding to a family trust. The transfer to the trust will be done only after receipt of an exemption under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from the Securities and Exchange Board of India. It is to be noted that such an arrangement will not result in any change in management and control of the Company.	23-Mar-16
Favourable Competition Appellate Tribunal Order - Penalty of Rs. 746.3 million set aside"	10-May-16

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Alkem announces closure of UK-MHRA inspection for its Bioequivalence Facility at Taloja".	7-Jun-16
Alkem announced certain restructuring of responsibilities between the senior management of the Company. The Joint Managing Directors and Executive Director would be responsible for the following functional areas of the Company's business: - Mr. Dhananjay Kumar Singh, Joint Managing Director, shall be responsible for specific Domestic Business units focusing on Acute and Chronic Therapies in addition to support functions namely Legal and Secretarial, Purchase, Distribution & Logistics and Human Resources. - Mr. Sandeep Singh, Joint Managing Director, shall be responsible for International Business, R & D including Biotech, Finance, Quality & Compliance, API and Formulation Manufacturing facilities for International Business. - Mr. Mritunjay Kumar Singh, Executive Director, shall be responsible for certain Domestic Business units focusing on Acute and Chronic Therapies, Generics and Healthcare in addition to Strategy & Business Development and Manufacturing Facilities for Domestic Business. - Mr. Dhananjay Kumar Singh, Mr. Sandeep Singh and Mr. Mritunjay Kumar Singh shall report to Executive Chairman for their respective functional areas of business. - Mr. Prabhat Agrawal, Chief Executive Officer, shall be responsible for the overall day to day operations of the Company and report to Mr. Dhananjay Kumar Singh, Mr. Sandeep Singh and Mr. Mritunjay Kumar Singh for their abovesaid respective roles and responsibilities.	27-Jun-16
Successful US FDA Inspection at Alkem's Bioequivalence Facility at Taloja where no 483s were issued	11-Aug-16
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Company's manufacturing facility located at Daman, India from September 20 to September 29, 2016. In this regard, the Company has received the inspection report which contains thirteen 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA.	29-Sep-16
Alkem Laboratories Ltd has informed BSE that the US FDA had conducted a Bio-analytical Inspection at the Company's manufacturing facility located at Daman, India from October 24 to October 28, 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the Company.	28-Oct-16
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Company's API (Active Pharmaceutical Ingredient) manufacturing facility located at Ankleshwar, India from 5th December to 9th December, 2016. In this regard, the Company has received the inspection report which contains three 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA	12-Dec-16
In furtherance to the intimation captioned "Update on US FDA Inspection at Alkem's Daman Facility" dated 29th September, 2016, this is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for its Daman formulation facility which was inspected in September 2016. The inspection has now been closed by the US FDA. In response to the Form 483 issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The US FDA has reviewed the CAPA and has found them acceptable	23-Dec-16
Alkem Laboratories Ltd has informed BSE regarding a Press Release dated February 07, 2017 titled "Alkem enters into an alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India".	7-Feb-17
US FDA had conducted an inspection at the Company's Bioequivalence facility located at Taloja, India from 10th July, 2017 to 14th July, 2017. At the end of the inspection, no Form 483 was issued.	14-Jul-17
US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 11th September, 2017 to 15th September, 2017. In this regard, the Company has received the inspection report which contains two 483 observations.	18-Sep-17
Mr. Sandeep Singh, Joint Managing Director of the Company has been appointed and re-designated as the "Managing Director" for a period of five years	17-Oct-17
US FDA had conducted an inspection at the Company's manufacturing facility located at St Louis, USA from 23rd October, 2017 to 27th October, 2017. At the end of the inspection, no Form 483 was issued	28-Oct-17
Mr. Prabhat Agrawal has resigned from the position of Chief Executive Officer & Key Managerial Personnel of the Company due to personal reason	31-Oct-17
US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Baddi	10-Jan-18
US FDA conducted an inspection at the Company's manufacturing facility located at Amaliya, Daman, India from 19th March, 2018 to 27th March, 2018. Post the inspection, the	28-Mar-18
Closure of US FDA Inspection at Alkem's manufacturing facility located at Amaliya, Daman	24-Jul-18
US FDA had conducted an inspection at the Company's Bioequivalence facility located at Taloja, Maharashtra from 8th November, 2018 to 14th November, 2018. No Form 483 issued	15-Nov-18

Updated as of 16 Nov 2018